<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7892C89D-DCEC-4F1F-93B4-090A53DAE319"><gtr:id>7892C89D-DCEC-4F1F-93B4-090A53DAE319</gtr:id><gtr:name>German Breast Group (GBG)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:department>London Research Institute (LIF)</gtr:department><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7892C89D-DCEC-4F1F-93B4-090A53DAE319"><gtr:id>7892C89D-DCEC-4F1F-93B4-090A53DAE319</gtr:id><gtr:name>German Breast Group (GBG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D74702EE-DC61-4418-A99A-12C6FE696E98"><gtr:id>D74702EE-DC61-4418-A99A-12C6FE696E98</gtr:id><gtr:name>The Francis Crick Institute</gtr:name><gtr:address><gtr:line1>1 Midland Road</gtr:line1><gtr:postCode>NW1 1AT</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D95FD8DB-7962-41E1-9432-6CB0BFCA1193"><gtr:id>D95FD8DB-7962-41E1-9432-6CB0BFCA1193</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Swanton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701935"><gtr:id>D7FE57D2-3206-45C1-9EBC-2CEF55398D00</gtr:id><gtr:title>Genomic Instability as a Therapeutic Target in Breast and Colorectal Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701935</gtr:grantReference><gtr:abstractText>Genetic information is contained in units of DNA in a cell called chromosomes. Normal cells rely upon checkpoints to control the passage of genetic information contained in chromosomes to daughter cells. The mitotic checkpoint, regulates the passage of genetic information before the formation of daughter cells and if this fails, cancers become resistant to death induced by the taxane breast cancer drug and develop resistance to other cancer drugs in the laboratory. Failure of the same checkpoint promotes gain or loss of whole chromosomes (called chromosomal instability, CIN cancers) associated with worse prognosis in cancer patients. 

Many patients with breast cancer experience side effects but derive limited or no benefit from taxane treatment. A CR-UK team will analyse breast cancer tissue from patients treated with taxanes within clinical trials to assess whether CIN is associated with taxane resistance. This may identify which patients may benefit from this treatment in the future. 

The CRUK team will identify how to selectively target CIN cancers to promote new approaches for anticancer drug discovery. These drugs may eventually limit the evolution of tumour drug resistance and have greater cancer-specificity, reducing side effects to normal tissue (skin, hair and white blood cells) with normal chromosome number.</gtr:abstractText><gtr:technicalSummary>Chromosomal instability (CIN) is associated with the acquisition of drug resistance and poorer prognosis in many solid tumours. Our work has focussed on the association of CIN with taxane resistance. We have identified several genes which when silenced by RNA interference (RNAi), impair a taxane induced mitotic arrest and promote paclitaxel resistance. Many of these genes promote centrosomal amplification, multinucleation and endoreduplication without drug exposure, indicating that aberrations in chromosomal segregation may serve as a marker of intrinsic taxane resistance. In agreement, we have established a correlation between increasing numerical-CIN (known as Chromosomal Numerical Heterogeneity or CNH) in breast and colorectal cancer cell lines and resistance to microtubule stabilising agents such as paclitaxel. The polygenic nature of multi-drug resistance, supported by our work, may explain the evolution of resistance to non-cross resistant cytotoxics in human tumours driven by genomic instability mechanisms such as CIN. Identifying vulnerable pathways within tumours harbouring specific patterns of genomic instability such as CNH may reveal novel oncogenic targets, enhance taxane sensitivity and limit the acquisition of multi-drug resistant disease.

Aims and Objectives
1. Assess the relationship between CNH and microtubule stabiliser response in breast and colorectal cancer.

2. Elucidate mechanisms of cancer cell survival in the presence of specific patterns of genomic instability (chromosomal or microsatellite instability) to:
 provide therapeutic cancer-specific targets 
 limit acquisition of taxane and multi-drug resistant disease.

Design and Methodology
Using established clinical trial samples in primary breast cancer (NeoTango) and FISH expertise, the association of CNH status with paclitaxel response will be assessed in vivo and a gene expression signature associated with CNH derived. 
A high throughput whole genome RNAi screen and an automated Acumen laser scanning cytometer will identify genomic instability-specific survival regulators in isogenic cancer cell lines deficient in mismatch repair or spindle assembly checkpoint components. 
Expression of validated candidates will be assessed in breast and colorectal cancer trial samples (CINATRA, TACT, NeoTANGO) for which genomic instability data will be available. Live cell microscopy will elucidate the mechanisms of death following silencing of CIN-survival candidate genes. 

Scientific and Medical Opportunities
Validated candidates may further understanding of mitotic deregulation and chromosome segregation in colorectal and breast cancer and provide suitable leads for future drug discovery programmes to delay multi-drug resistance by targeting specific mechanisms of genomic instability. This work may optimise the selection of patients with disease sensitive to microtubule inhibitors and provide therapeutic targets in taxane-resistant disease.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2029779</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PREDICT Consortium</gtr:description><gtr:id>B45C49A2-5324-4E63-916C-9F9E1D7C45E5</gtr:id><gtr:impact>1 paper in submission with the NEJM in the second round of review. Mulit-disciplinary collaboration between clinical trial centres in Europe and Cancer Research UK and the Royal Marsden Hospital. Funded by the European Union Framework Program 7 (5.8 million Euro grant over 3 years).</gtr:impact><gtr:outcomeId>CjZQy8J1xVG-1</gtr:outcomeId><gtr:piContribution>Myself and the research team were the first to demonstrate that RNA interference screening datasets could be used to predict paclitaxel response in breast cancer. This approach led my group to initiate the PREDICT Consortium (www.predictconsortium.eu) which was awarded a 5.8 million euro EU FP7 grant in Jan 2011.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Manchester Institute</gtr:department><gtr:description>TRACERx Consortium</gtr:description><gtr:id>F805A93A-AF8E-4A1C-B492-6D4E986DF9B7</gtr:id><gtr:impact>Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Gr&amp;ouml;nroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee SM, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom W, Teefe E, Chen SC, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, Swanton C.
Science. 2014 Oct 10;346(6206):251-6. doi: 10.1126/science.1253462


Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.
Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C.
PLoS Biol. 2014 Jul 8;12(7):e1001906.</gtr:impact><gtr:outcomeId>543d35e42e43d9.77674838-1</gtr:outcomeId><gtr:partnerContribution>My colleagues Caroline Dive (Circulating tumour cells) and Dr Jacqui Shaw (circulating free DNA) are providing the circulating biomarker expertise for this study. My clinical colleagues at 5 national ECMC's are providing the patient material to work on for this cancer evolution study.</gtr:partnerContribution><gtr:piContribution>I am the chief investigator for this study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>PLOIDYNET Consortium</gtr:description><gtr:id>84CC734E-006A-4630-954B-CCF47653C67D</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>563ca9945db368.55674756-1</gtr:outcomeId><gtr:partnerContribution>analysis of tracerx lung tumour samples and their aneuploid nature</gtr:partnerContribution><gtr:piContribution>Bioinformatic analysis of aneuploid tumours</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>German Breast Group (GBG)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>RESPONSIFY EU FP7 Consortium</gtr:description><gtr:id>D6BC57C3-B08A-4481-B7F5-5EAA642D9730</gtr:id><gtr:impact>none yet, grant just commenced</gtr:impact><gtr:outcomeId>mmtyr6bEZxC-1</gtr:outcomeId><gtr:partnerContribution>Derive rna interference screening approaches to identify molecular regulators of drug sensitivity.</gtr:partnerContribution><gtr:piContribution>I am a joint applicant on this grant to identify response biomarkers to anti-her2 and anti-angiogenic therapies in breast cancer,</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>3 visits: Fund raisers: CR-UK; Patient relatives</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>008CCF81-8744-4EEC-A448-A71ADD7B6A62</gtr:id><gtr:impact>We have led 3 sessions in my laboratory demonstrating our MRC funded research activity to laypersons (high networth individuals /or patient relatives/or CR-UK fundraisers).

A great deal of interest was raised by our group. The Bobby Moore Foundation have returned for a further educational/promotional visit as a result of our first demonstration. A family of a patient has donated &amp;pound;7000 to my research team.</gtr:impact><gtr:outcomeId>7B63D4A9273</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chair of the NCRI</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E317E4B9-9B16-4BE5-99D4-89B016F544C0</gtr:id><gtr:impact>AS NCRI chair i was involved in patient and consumer discussions and publicising national research findings for public understanding.

Discussions around Health economic impact of medical care</gtr:impact><gtr:outcomeId>563cad9c0e5a98.46100451</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Prostate Cancer Foundation</gtr:description><gtr:fundingOrg>Prostate Cancer Foundation</gtr:fundingOrg><gtr:id>53F46B44-86BF-45EA-8984-F346352D3AEA</gtr:id><gtr:outcomeId>E5L9HALyE3T</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>RESPONSIFY</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>2682E6ED-4420-4850-A671-371E55AB9F10</gtr:id><gtr:outcomeId>Fh4ceTZVj3W</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TRACERx Grant award</gtr:description><gtr:end>2023-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>E48F7857-3CDD-40DA-85A8-D27D0AA0FC89</gtr:id><gtr:outcomeId>543d363c60b951.67547121</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>390000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees Trust</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>9732AE66-AB42-4096-9516-5310289416FA</gtr:id><gtr:outcomeId>ZwxSQbcq3Qz</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK BIDD Genomics Grant</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>8BCBB7F5-5EC5-4AAF-9E27-EB151E02776B</gtr:id><gtr:outcomeId>dZx6bmq8Lxh0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PREDICT Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics (5.8m euros across 11 participants)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>F67A3BF1-40D8-46E8-9477-AF7B618F846F</gtr:id><gtr:outcomeId>jghGYZn7on90</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Breast Cancer Research Foundation</gtr:description><gtr:fundingOrg>The Breast Cancer Research Foundation</gtr:fundingOrg><gtr:id>0B6A15E1-E2B3-4FBC-A3FF-062DD382DCA0</gtr:id><gtr:outcomeId>DWY3DqNrmMd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK Scientific Executive Board</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>555012D1-1F78-49A9-909E-9301524893E9</gtr:id><gtr:outcomeId>ER8Zbmm9ZZN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Consolidator grant</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>EEDEAA91-11B3-4F1F-9AE8-83598E41690C</gtr:id><gtr:outcomeId>563caa1dc22756.78486777</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>St Georges House NHS Public Policy Review</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD57DA8C-68A0-4DF8-B33F-B9DB0C407762</gtr:id><gtr:outcomeId>563cad09e2a483.13665635</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have published a method demonstrating that RNA interference techniques can be used to identify genes expressed in tumours that are predictive of drug response in patients with primary breast cancer.</gtr:description><gtr:id>DBBB1CD6-B175-451F-8423-64881203EC12</gtr:id><gtr:impact>This has led to many invited lectures at Personalised Medicines conferences including NCRI and ESMO 2011 and a Harvard personalised medicines conference in 2010. There has also been significant interest from the Pharmaceutical industry about our predictive biomarker discovery methodologies with emerging collaborations with Roche, Novartis and Pfizer.</gtr:impact><gtr:outcomeId>CSBHrxnN27j</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Functional Metagene Approach to Accelerate Biomarker Discovery in Cancer Medicine</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5DB670B9-F94B-4776-9B92-AFB564022FA0</gtr:id><gtr:title>Implications of intratumour heterogeneity for treatment stratification.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00d1343e8c6b1b81e10c140a61ee7863"><gtr:id>00d1343e8c6b1b81e10c140a61ee7863</gtr:id><gtr:otherNames>Crockford A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12498_28_24115146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4595585-2ADB-4A73-A227-D57C3952277E</gtr:id><gtr:title>A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6749dcf358f80899fde339bc3719fe7a"><gtr:id>6749dcf358f80899fde339bc3719fe7a</gtr:id><gtr:otherNames>Endesfelder D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>HJpkYvQWPcD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6CCB6DD-BBFD-444E-A8A5-EB6C64048CBB</gtr:id><gtr:title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12498_28_22397650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7161D6A-33B2-4343-B41F-DDAC2F79C7D4</gtr:id><gtr:title>Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4554e2051f9b323489c56abb888aea6a"><gtr:id>4554e2051f9b323489c56abb888aea6a</gtr:id><gtr:otherNames>Abbosh C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>5aa69c1fab20d6.82090901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15338CA3-F1FE-4B03-83EE-97129ACE1162</gtr:id><gtr:title>A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/223ced8f335cf33dc2d6eda4d6733112"><gtr:id>223ced8f335cf33dc2d6eda4d6733112</gtr:id><gtr:otherNames>Natrajan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12498_28_22362584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AD717B3-F000-41AA-9490-5093AAEFAF7E</gtr:id><gtr:title>Chromosomal instability confers intrinsic multidrug resistance.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed352dfad2c00c9216325a6d59574edd"><gtr:id>ed352dfad2c00c9216325a6d59574edd</gtr:id><gtr:otherNames>Lee AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>eMV1ce7bwfx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44624A7E-FACC-46C2-B2CE-E165797DED30</gtr:id><gtr:title>Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12498_28_24122851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FF58F3B-8E5B-4969-B5F9-5FABC2D91BB6</gtr:id><gtr:title>Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5f89bc266f10341c365606e24326bd0"><gtr:id>e5f89bc266f10341c365606e24326bd0</gtr:id><gtr:otherNames>Swanton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>4CF659D8BDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0294C24B-3A96-492A-AC3B-FE26CA4F1910</gtr:id><gtr:title>Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e302316b83e1009ad465a8766b3e694"><gtr:id>7e302316b83e1009ad465a8766b3e694</gtr:id><gtr:otherNames>Roylance R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>GdcCbsN9qL3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35BC362E-5F07-4B19-B04A-9D731C5684C7</gtr:id><gtr:title>A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06792f82025d4e6c72a5559c19c5833f"><gtr:id>06792f82025d4e6c72a5559c19c5833f</gtr:id><gtr:otherNames>Brunetto AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>RtwYaoGQKmR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32C9CB1B-42C1-4E39-B849-36D9F4E5E5A6</gtr:id><gtr:title>SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/965f66374803d1235c359b4723d40be4"><gtr:id>965f66374803d1235c359b4723d40be4</gtr:id><gtr:otherNames>Kanu N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>563ca862cde8e9.97888786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82718919-9DF0-4E99-BC09-A29937A17685</gtr:id><gtr:title>HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef43335b3143dd045d67808e73ff4c84"><gtr:id>ef43335b3143dd045d67808e73ff4c84</gtr:id><gtr:otherNames>Adelman CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_12498_28_24005329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF0A5213-409F-4AFC-BE73-A37FCE56B737</gtr:id><gtr:title>Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5f89bc266f10341c365606e24326bd0"><gtr:id>e5f89bc266f10341c365606e24326bd0</gtr:id><gtr:otherNames>Swanton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>6BC28ECBA93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BC448CC-FF36-43B4-A729-D51DF07D5D41</gtr:id><gtr:title>Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6749dcf358f80899fde339bc3719fe7a"><gtr:id>6749dcf358f80899fde339bc3719fe7a</gtr:id><gtr:otherNames>Endesfelder D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>543d347032ded4.79263669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C1DD2E2-211F-4CB5-96C7-E6D305DD68AC</gtr:id><gtr:title>Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0be617becd7b5da652b95c7ac3fce687"><gtr:id>0be617becd7b5da652b95c7ac3fce687</gtr:id><gtr:otherNames>Ng CKY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>543d34710ceb96.73204410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89606003-86E7-4D99-B64F-4E5CD26672C1</gtr:id><gtr:title>Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ae2195e63b486814855772fed3eea6b"><gtr:id>2ae2195e63b486814855772fed3eea6b</gtr:id><gtr:otherNames>Chapman MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_12498_28_22173169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E1497FE-9110-4CF2-96A2-35C3CCFE8BD8</gtr:id><gtr:title>CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed352dfad2c00c9216325a6d59574edd"><gtr:id>ed352dfad2c00c9216325a6d59574edd</gtr:id><gtr:otherNames>Lee AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>MU7VeATALap</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC4F785A-F1B1-4CD3-8B59-F9304ED3C18B</gtr:id><gtr:title>The causes and consequences of genetic heterogeneity in cancer evolution.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7ec863bb895cd45877117902a3527cc"><gtr:id>c7ec863bb895cd45877117902a3527cc</gtr:id><gtr:otherNames>Burrell RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_12498_28_24048066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0C0E144-8EBC-4FE6-BE91-F8335036B3EB</gtr:id><gtr:title>The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program &amp;quot;CASCADE&amp;quot;.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bd0e50d30980d5f5eedfd76564ca1dd"><gtr:id>1bd0e50d30980d5f5eedfd76564ca1dd</gtr:id><gtr:otherNames>Savas P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58c7f699a0fa27.08804945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>794BA4B4-26A8-4989-94E7-E9445AB1F291</gtr:id><gtr:title>Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_12498_28_22362593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCDD9D3D-36FB-47B6-B8DC-BC08DA0EA8B2</gtr:id><gtr:title>Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a00e5438cd5bc01dd9a7a079a217bb6"><gtr:id>6a00e5438cd5bc01dd9a7a079a217bb6</gtr:id><gtr:otherNames>Goh G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58c7f81ced67f4.03620001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAFBACAE-331E-48E5-A9DE-FD49E4834AF2</gtr:id><gtr:title>Chromosomal instability determines taxane response.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5f89bc266f10341c365606e24326bd0"><gtr:id>e5f89bc266f10341c365606e24326bd0</gtr:id><gtr:otherNames>Swanton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BEA943A027B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>734A8AC2-0FFA-49FF-9445-10CF84254154</gtr:id><gtr:title>Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f6924f8765fc02490873fd4b290945"><gtr:id>99f6924f8765fc02490873fd4b290945</gtr:id><gtr:otherNames>Li Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>C6YhtLHFbPe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AE80609-D409-49C2-A94C-80A1B8C82132</gtr:id><gtr:title>Cancer therapeutics through an evolutionary lens.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5f89bc266f10341c365606e24326bd0"><gtr:id>e5f89bc266f10341c365606e24326bd0</gtr:id><gtr:otherNames>Swanton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>5aa69c21573cd1.90054137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6341AD2-AE12-4BB4-8565-EF0526CDBC50</gtr:id><gtr:title>Chromosomal instability drives metastasis through a cytosolic DNA response.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2af6f06c4d0e909a1291f0e91212e16f"><gtr:id>2af6f06c4d0e909a1291f0e91212e16f</gtr:id><gtr:otherNames>Bakhoum SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5aa69c20b7e8f4.50995982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99DCCBF0-5B28-48D4-A5FD-42FC641163C5</gtr:id><gtr:title>Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19ccad6cd2a8ba4894acba2cc6a199eb"><gtr:id>19ccad6cd2a8ba4894acba2cc6a199eb</gtr:id><gtr:otherNames>Juul N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>FR7yQrqt9KH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEABA922-2D6A-4906-B430-5C2FE447E49A</gtr:id><gtr:title>Acquired resistance to crizotinib from a mutation in CD74-ROS1.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e63997bc466ab652e033701241210d4"><gtr:id>4e63997bc466ab652e033701241210d4</gtr:id><gtr:otherNames>Gerlinger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12498_28_24047073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD31DDA-F06D-4943-8E79-E2A1F59F5163</gtr:id><gtr:title>FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/244c1b7e8391220a156836a146be7dd0"><gtr:id>244c1b7e8391220a156836a146be7dd0</gtr:id><gtr:otherNames>McKeen HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>Ace4vhQwHPE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40067AC7-FAA8-4A97-974B-275FA6C23901</gtr:id><gtr:title>Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed352dfad2c00c9216325a6d59574edd"><gtr:id>ed352dfad2c00c9216325a6d59574edd</gtr:id><gtr:otherNames>Lee AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>E9F760BEE4A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E6D5556-C479-4949-9FFA-EEDA7DBA51AF</gtr:id><gtr:title>The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26fa9474fc9dc6146887ae60ec41d25a"><gtr:id>26fa9474fc9dc6146887ae60ec41d25a</gtr:id><gtr:otherNames>Ahmed AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>59EC5FCD38C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64B6179A-BBAB-4300-8D42-4E339B864D6A</gtr:id><gtr:title>Paradoxical relationship between chromosomal instability and survival outcome in cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cc223b70309b702e5095177290c13d6"><gtr:id>2cc223b70309b702e5095177290c13d6</gtr:id><gtr:otherNames>Birkbak NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>CnmK7FNrbdN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E3C9995-8E97-44EA-9DAB-C92CDE2481F5</gtr:id><gtr:title>Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df0325b2042f127a06f59c70f68e3826"><gtr:id>df0325b2042f127a06f59c70f68e3826</gtr:id><gtr:otherNames>Dewhurst SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn><gtr:outcomeId>543d3472cdc5a4.69568892</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701935</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>